Cardiac Science Announces Existing Shareholders to Invest Additional Capital.

Business Editors/Health & Medical Writers

BIOWIRE2K

IRVINE, Calif.--(BW HealthWire)--May 23, 2000

Cardiac Science Inc. (OTCBB:DFIB), the developer of Powerheart(R), the only hospital monitor that provides life-saving defibrillation within seconds and without the aid of hospital staff, announced it has received verbal commitments from its existing investor group, as well as several new Swiss and US investors, to purchase in excess of $10 million of equity securities.

The Company anticipates that the private placement will be completed in June 2000.

"Based upon our prior experience with many of these investors, we have a high degree of confidence in closing on these commitments. Our existing shareholders have continuously demonstrated strong support for the company and our mission that all in-hospital cardiac patients have access to defibrillation within seconds should they suffer a life-threatening heart rhythm," said Raymond W. Cohen, president and chief executive officer. "This additional capital will allow us to continue to make significant investments in marketing programs to drive adoption of our initial commercial product, the Powerheart, and complete the development of our next embodiment of our core technology, the Automatic Defibrillation Module for use with standard bedside patient monitors widely used in hospitals throughout the world."

ABOUT CARDIAC SCIENCE

Cardiac Science develops and markets life-saving external cardiac defibrillator devices and proprietary tachyarrhythmia detection software technology that monitor and automatically treat cardiac arrest patients.

Shipments of our initial commercial product, the Powerheart, began on Dec. 31, 1999 and the Company generated revenue of $624,642 for the first quarter 2000 attributed to the sale of 120 Powerheart bedside defibrillator-monitors and related proprietary disposable defibrillation electrodes to its US distribution partner Medtronic Physio-Control, the Arizona Heart Hospital and numerous international distributors. As of April 1, the company had an existing backlog of orders of approximately $500,000, which it expects to fill within the second quarter.

Powerheart continuously monitors in-hospital patients at risk of sudden cardiac arrest, instantly detects the onset of a life-threatening heart rhythm, and when appropriate, automatically delivers defibrillation shocks within seconds and without human intervention to re-establish the heart's normal rhythm. RHYTHMx ECD(TM) detection and defibrillation software technology, our core proprietary technology platform, has multiple applications including use in external defibrillators and existing standard bedside patient monitors widely used in hospitals throughout the world.

The company has an exclusive agreement with Medtronic Physio-Control, a division of Medtronic, Inc., the worldwide market leader in external defibrillator products, to distribute the Powerheart in the U.S., Canada, and nine European countries. Cardiac Science's global network consists of prominent distributors in 41 countries encompassing Asia, the Middle East, Europe, South America and North America.

Cardiac Science is ISO 9001 certified. These are quality standards adopted by over 90 countries and set forth by the International Organization for Standardization. Powerheart has U.S. and international regulatory clearance including certification to the European Union's Medical Devices Directive, which allows the company to affix the CE Mark to offer its products for sale in the European Union and European Economic area. For more information, visit www.cardiacscience.com.

This news release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. Such forward looking statements include, but are not limited to: The Company's ability to complete a equity financing in June 2000; The Powerheart's safety and efficacy, it's ability to increase survival rates for in-hospital cardiac arrest victims, its ability to improve patient-care, lessen patient debilitation and shorten hospital stays; The Company's ability to generate revenue, ship product, fulfill its current backlog of orders and develop new products. Cardiac Science cautions that these statements are qualified by important factors that could cause actual results to differ materially from those reflected by the forward-looking statements. Other factors include, but are not limited to: hospital operations; market and clinical users' acceptance of new and existing products; impact of competitive products and pricing; and changing market conditions. Information on these and other factors are detailed in the Company's Form 10-K for the year ending December 31, 1999 and other documents filed with the Securities and Exchange Commission. The Powerheart and RHYTHMx ECD and Automatic Defibrillation Module are trademarks of Cardiac Science Inc.